Lipum AB (publ) has published the interim report Q2 for the period January-June 2024. Below is a summary, a complete report (only in Swedish) is available on the company's website.
CEO Ola Sandborgh comments: “It is with a smile on my lips, I look back to the first half of 2024 which has been filled with activities indicating progress and results in line with expectations. We will in 2024, be able to complete the phase 1 program and at the same time, with support from the recently completed rights issue, initiate the preparations of an exciting and potentially value increasing phase 2 program!”
Financial summary January – June 2024
- Other operating income: KSEK 315 (64)
- Result after financial items: KSEK -28 109 (-21 122)
- Cash and cash equivalents as of June 30: KSEK 20 131 (12 364)
Significant events during the period January – June 2024
- Lipum strengthens its protection of the drug candidate SOL-116 through a patent application for inflammation-driven cancer.
- Lipum has been granted SEK 2,8 million from Swelife.
- Lipum announces SEK 79,7 million as outcome of the rights issue and receives loan commitment of SEK 20 million.
- Lipum enters a strategic manufacturing agreement with NorthX Biologics.
- Ingemar Kihlström elected as new Chairman and Åsa Magnusson elected as new Board member.
- The multiple dose part of the phase I clinical study is completed.
Significant events after the period
- Lipum has received a negative preliminary report regarding the audit of the Horizon 2020 project.
CEO Ola Sandborgh comments on the report in a live webcast on August 9 at 09:00 link.
The complete report (only in Swedish) is available at www.lipum.se.